IL-6 in diabetes and cardiovascular complications

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3595-3603

  Qu, Dan ^a   Liu, Jian ^a   Lau, Chi Wai ^a   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cardiovascular diseases; diabetes; inflammation; interleukin 6

Indexed keywords

INTERLEUKIN 6;

CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; METABOLIC REGULATION; MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; INFLAMMATION; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INFLAMMATION; INTERLEUKIN-6; OBESITY; SIGNAL TRANSDUCTION;

EID: 84904558110     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12713     Document Type: Review

References (79)

1. Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, etal. (2007). Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 27: 2372-2383.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal (2013). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
3. Ash Z, Emery P, (2012). The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 12: 1277-1289.
4. Bacon K, Gearing A, Camp R, (1990). Induction of in vitro human lymphocyte migration by interleukin 3, interleukin 4, and interleukin 6. Cytokine 2: 100-105.
5. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, etal. (2000). Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338-3342.
6. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC, (2003). Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101-2104.
7. Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MF, Coudeyre JC, etal. (2006). The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 187: 82-91.
8. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, etal. (2006). Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688-2697.
9. Chava KR, Karpurapu M, Wang D, Bhanoori M, Kundumani-Sridharan V, Zhang Q, etal. (2009). CREB-mediated IL-6 expression is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. Arterioscler Thromb Vasc Biol 29: 809-815.
10. Chiu JJ, Chien S, (2011). Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91: 327-387.
11. Chiu JJ, Chen LJ, Lee CI, Lee PL, Lee DY, Tsai MC, etal. (2007). Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress. Blood 110: 519-528.
12. Chou CH, Lai SL, Chen CN, Lee PH, Peng FC, Kuo ML, etal. (2013). IL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regeneration. PLoS ONE 8: e66268.
13. Collaboration IRGCERF, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, etal. (2012). Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379: 1205-1213.
14. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, etal. (2005). The IL-6R alpha chain controls lung CD4 + CD25 + Treg development and function during allergic airway inflammation in vivo. J Clin Invest 115: 313-325.
15. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, etal. (2008). Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105: 13163-13168.
16. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, etal. (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489.
17. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK, (2004). Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643-1648.
18. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, etal. (2005). Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115: 3494-3505.
19. Frieling JT, van Deuren M, Wijdenes J, van der Meer JW, Clement C, van der Linden CJ, etal. (1995). Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis 171: 469-472.
20. Garbers C, Janner N, Chalaris A, Moss ML, Floss DM, Meyer D, etal. (2011a). Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 286: 14804-14811.
21. Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, etal. (2011b). Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 286: 42959-42970.
22. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, etal. (1999). Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-1146.
23. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, etal. (1989). Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710.
24. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M, (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234.
25. Hansson GK, (2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
26. Hansson GK, Robertson AK, Soderberg-Naucler C, (2006). Inflammation and atherosclerosis. Annu Rev Pathol 1: 297-329.
27. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L, (1998). IL-6-type cytokine signalling through the gp130/JAK/STAT pathway. Biochem J 334: 297-314.
28. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F, (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (Pt 1): 1-20.
29. Hideshima T, Nakamura N, Chauhan D, Anderson KC, (2001). Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000.
30. Holmes AG, Mesa JL, Neill BA, Chung J, Carey AL, Steinberg GR, etal. (2008). Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J Endocrinol 198: 367-374.
31. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, etal. (1992). Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 148: 2175-2180.
32. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kasahara T, Kano S, etal. (1993). Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines. Atherosclerosis 104: 61-68.
33. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP, (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379: 1214-1224.
34. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, etal. (2001). Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167.
35. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, etal. (1996). Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11: 88-95.
36. Kristiansen OP, Mandrup-Poulsen T, (2005). Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 (Suppl. 2): S114-S124.
37. Loppnow H, Buerke M, Werdan K, Rose-John S, (2011). Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med 15: 484-500.
38. Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, etal. (2014). Circulating Inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 63: 1115-1123.
39. Marin V, Montero-Julian FA, Gres S, Boulay V, Bongrand P, Farnarier C, etal. (2001). The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 167: 3435-3442.
40. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, etal. (2010). Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53: 2431-2441.
41. McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, etal. (2010). Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 184: 7219-7228.
42. Md Yusof MY, Emery P, (2013). Targeting interleukin-6 in rheumatoid arthritis. Drugs 73: 341-356.
43. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, etal. (1993). Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126.
44. Orshal JM, Khalil RA, (2004). Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 43: 434-444.
45. Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK, (1998). Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 508: 949-953.
46. Pedersen BK, (2000). Exercise and cytokines. Immunol Cell Biol 78: 532-535.
47. Pedersen BK, (2007). IL-6 signalling in exercise and disease. Biochem Soc Trans 35 (Pt 5): 1295-1297.
48. Peters M, Muller AM, Rose-John S, (1998). Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92: 3495-3504.
49. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334.
50. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP, (2011). A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 219: 734-736.
51. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, etal. (2008). Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111: 1021-1028.
52. Richez C, Barnetche T, Khoryati L, Duffau P, Kostine M, Contin-Bordes C, etal. (2012). Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage. J Rheumatol 39: 1192-1197.
53. Rose-John S, (2012). IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8: 1237-1247.
54. Rose-John S, Heinrich PC, (1994). Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300 (Pt 2): 281-290.
55. Ruotsalainen E, Stancakova A, Vauhkonen I, Salmenniemi U, Pihlajamaki J, Punnonen K, etal. (2010). Changes in cytokine levels during acute hyperinsulinemia in offspring of type 2 diabetic subjects. Atherosclerosis 210: 536-541.
56. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, etal. (2009). Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 203: 610-614.
57. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S, (2011). The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813: 878-888.
58. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, etal. (2000). Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101: 1372-1378.
59. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, etal. (2012). Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32: 281-290.
60. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, etal. (2007). Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56: 2541-2546.
61. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ, (2006). IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69: 164-177.
62. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, etal. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
63. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B, (2000). Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529 (Pt 1): 237-242.
64. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, etal. (2013). Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 229: 174-181.
65. Taga T, Kishimoto T, (1997). Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819.
66. Tanaka T, Narazaki M, Kishimoto T, (2012). Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199-219.
67. Tehrani DM, Gardin JM, Yanez D, Hirsch CH, Lloyd-Jones DM, Stein PK, etal. (2013). Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study. Atherosclerosis 231: 246-251.
68. Van Snick J, (1990). Interleukin-6: an overview. Annu Rev Immunol 8: 253-278.
69. Voros G, Maquoi E, Collen D, Lijnen HR, (2003). Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 1625: 36-42.
70. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T, (1989). The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169: 333-338.
71. Waetzig GH, Rose-John S, (2012). Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 16: 225-236.
72. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, etal. (2002). Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79.
73. Wang D, Liu Z, Li Q, Karpurapu M, Kundumani-Sridharan V, Cao H, etal. (2007). An essential role for gp130 in neointima formation following arterial injury. Circ Res 100: 807-816.
74. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, etal. (2013). Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36: 166-175.
75. Weber C, Noels H, (2011). Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410-1422.
76. Weiss TW, Arnesen H, Seljeflot I, (2013). Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism 62: 1008-1013.
77. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, etal. (1998). IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320.
78. Yuen DY, Dwyer RM, Matthews VB, Zhang L, Drew BG, Neill B, etal. (2009). Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes 58: 1086-1095.
79. Zhang J, Li Y, Shen B, (2003). PI3-K/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells. Cancer Cell Int 3: 1.